

# Manali Kamdar

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11465040/publications.pdf>

Version: 2024-02-01

41  
papers

1,513  
citations

516710

16  
h-index

330143

37  
g-index

42  
all docs

42  
docs citations

42  
times ranked

2391  
citing authors

#	ARTICLE	IF	CITATIONS
1	Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzumab for treatment-naïve chronic lymphocytic leukaemia (ELEVATE-TN): a randomised, controlled, phase 3 trial. <i>Lancet</i> , The, 2020, 395, 1278-1291.	13.7	393
2	Outcomes of COVID-19 in patients with CLL: a multicenter international experience. <i>Blood</i> , 2020, 136, 1134-1143.	1.4	248
3	PD-1 blockade for relapsed lymphoma post-“allogeneic hematopoietic cell transplant: high response rate but frequent GVHD. <i>Blood</i> , 2017, 130, 221-228.	1.4	214
4	Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naïve chronic lymphocytic leukemia. <i>Leukemia</i> , 2022, 36, 1171-1175.	7.2	72
5	Burkitt lymphoma in the modern era: real-world outcomes and prognostication across 30 US cancer centers. <i>Blood</i> , 2021, 137, 374-386.	1.4	59
6	COVID-19 in patients with CLL: improved survival outcomes and update on management strategies. <i>Blood</i> , 2021, 138, 1768-1773.	1.4	53
7	PD-1 Blockade in Mediastinal Gray-Zone Lymphoma. <i>New England Journal of Medicine</i> , 2017, 377, 89-91.	27.0	52
8	Single-route CNS prophylaxis for aggressive non-Hodgkin lymphomas: real-world outcomes from 21 US academic institutions. <i>Blood</i> , 2022, 139, 413-423.	1.4	50
9	Randomized phase 2 trial of polatuzumab vedotin (pola) with bendamustine and rituximab (BR) in relapsed/refractory (r/r) FL and DLBCL. <i>Journal of Clinical Oncology</i> , 2018, 36, 7507-7507.	1.6	45
10	Adult cord blood transplant results in comparable overall survival and improved GRFS vs matched related transplant. <i>Blood Advances</i> , 2020, 4, 2227-2235.	5.2	36
11	Improved survival with combined modality therapy in the modern era for primary mediastinal B-cell lymphoma. <i>American Journal of Hematology</i> , 2016, 91, 476-480.	4.1	25
12	HIV-associated Burkitt lymphoma: outcomes from a US-UK collaborative analysis. <i>Blood Advances</i> , 2021, 5, 2852-2862.	5.2	24
13	Venetoclax retreatment of patients with chronic lymphocytic leukemia after a previous venetoclax-based regimen. <i>Blood Advances</i> , 2022, 6, 4553-4557.	5.2	22
14	Outcomes of Burkitt lymphoma with central nervous system involvement: evidence from a large multicenter cohort study. <i>Haematologica</i> , 2021, 106, 1932-1942.	3.5	21
15	ASTCT, CIBMTR, and EBMT clinical practice recommendations for transplant and cellular therapies in mantle cell lymphoma. <i>Bone Marrow Transplantation</i> , 2021, 56, 2911-2921.	2.4	21
16	A multicenter retrospective study of polatuzumab vedotin in patients with large B-cell lymphoma after CAR T-cell therapy. <i>Blood Advances</i> , 2022, 6, 2757-2762.	5.2	19
17	Improved Survival With Radiation Therapy in Stage I-II Primary Mediastinal B Cell Lymphoma: A Surveillance, Epidemiology, and End Results Database Analysis. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 94, 126-132.	0.8	18
18	Five-year outcomes of the S1106 study of R-hyper-CVAD vs R-bendamustine in transplant-eligible patients with mantle cell lymphoma. <i>Blood Advances</i> , 2019, 3, 3132-3135.	5.2	18



#	ARTICLE	IF	CITATIONS
37	Combination of Idasanutlin, Venetoclax and Obinutuzumab in Patients with Relapsed or Refractory (R/R) Non-Hodgkin Lymphoma (NHL): Results from a Phase I/II Study. Blood, 2020, 136, 30-31.	1.4	1
38	Secondary CNS involvement of ALK-negative anaplastic large cell lymphoma. American Journal of Hematology, 2017, 92, 1267-1268.	4.1	0
39	Post-Transplant Diffuse Large B Cell Lymphoma with Non Germinal Center B-Cell Subtype Frequently Lacks Programmed Cell Death Ligand (PD-L1) Overexpression Which May Influence Overall Outcomes. Blood, 2016, 128, 3054-3054.	1.4	0
40	Addition of Rituximab to High-Dose Methotrexate Regimens Improves Complete Response Rates and Median Overall Survival in Non-Germinal Center Primary CNS Lymphoma. Blood, 2018, 132, 4217-4217.	1.4	0
41	Abstract CT522: Feasibility and safety of a novel CD19 CAR T cell therapy in adults with R/R B-NHL. Cancer Research, 2022, 82, CT522-CT522.	0.9	0